Floatz logo

ETOPOSIDE

T Lymphoblastic Leukemia/Lymphoma

Institute of Hematology & Blood Diseases Hospital, ChinaSmall moleculePhase 3Active
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the T Lymphoblastic Leukemia/Lymphoma cohort.

Asset / SponsorPhaseRating
Fludarabine
Institute of Hematology & Blood Diseases Hospital, China
Phase 2B
Tucidinostat
Zhejiang University
Phase 2B
Humanized Cd7 Car-T Cells
The First Affiliated Hospital of Soochow University
Phase 1/2CC
Supcd7 Cart Cells
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2CC
Anti-Cd7 Car-T Cells
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 1CC
cd19-ucart
Shenzhen University General Hospital
Phase 1CC
ucd7 cart
Institute of Hematology & Blood Diseases Hospital, China
Phase 1CC
Autologous Cd7-Targeting Car T Cells
Hebei Senlang Biotechnology Inc., Ltd.
Phase 2NR

Same molecule, other indications

ETOPOSIDE is also rated in:

acute megakaryoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute myeloblastic leukemia with maturationDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →